Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Pfizer Offloads Troubled ADHD Products To Manufacturer Tris

Executive Summary

Tris acquires Pfizer subsidiary Nextwave, which developed pair of ADHD drugs using Tris delivery technology. Lilly gets oral CGRP candidate from Chugai, while Dova signs US co-promotion partner for Doptelet.

Advertisement

Related Content

Just What We Were Looking For: Roche Pays €70m For Preclinical Anti-CD25 Asset
Midatech Divests US Unit To Focus On Its Rival Drug To Novartis' Sandostatin LAR
Verastem’s Copiktra Gets Early Approval To Challenge Zydelig, Venclexta In Third-Line CLL
Novo Nordisk Adds Momentum To Oral Semaglutide With Good PIONEER 5 Data
Dova’s Doptelet Gets First-To-Market Edge In Thrombocytopenia, Ahead Of Shionogi
Pfizer Contract Manufacturer Slammed By US FDA For Dissolution Failures And Leaking Bottles
Pfizer's Avelumab Makes Its Debut, In Rare Form Of Skin Cancer
PIPELINE WATCH - Four Launches, Two Approvals And Six Orphan Drug Designations
Prima Shifts Focus To LAG-3 After Immutep Deal
Pfizer acquires NextWave after surfing ADHD drug to US approval

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC123918

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel